Tesamorelin vs AOD-9604
A comprehensive, data-driven comparison of Tesamorelin (Egrifta) and AOD-9604 (Advanced Obesity Drug). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tesamorelin Egrifta, TH9507 | AOD-9604 Advanced Obesity Drug, Tyr-hGH Fragment 176-191 |
|---|---|---|
| FDA Status | FDA Approved | Phase 2 (failed; reclassification pending) |
| Category | Growth Hormone | Weight Loss |
| Primary Use | HIV-associated lipodystrophy | Fat loss and metabolism enhancement |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $200 - $1,500/mo | $30 - $60/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2mg daily | 300mcg daily |
| Frequency | Daily | Daily |
| Mechanism | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production | Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without affecting blood sugar or IGF-1 |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Low |
| Clinical Trial Phase | Approved | Phase 2 |
Key Differences
- 1Tesamorelin is FDA-approved, while AOD-9604 is currently phase 2 (failed; reclassification pending).
- 2AOD-9604 is generally more affordable ($30 - $60/mo) compared to Tesamorelin ($200 - $1,500/mo).
- 3Tesamorelin has high-quality evidence, while AOD-9604 has low-quality evidence.
- 4They belong to different categories: Tesamorelin (Growth Hormone) vs AOD-9604 (Weight Loss).
Which Is Better For...
Tesamorelin
Those seeking an FDA-approved treatment with established safety data
AOD-9604
More budget-friendly option with lower monthly costs
AOD-9604
Fewer commonly reported side effects
Tesamorelin
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
| AOD-9604 | $30 - $60/mo | Phase 2 (failed; reclassification pending) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. AOD-9604 works via Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis. They differ in FDA approval status, efficacy data, and cost.
Tesamorelin typically costs $200 - $1,500/mo, while AOD-9604 costs $30 - $60/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tesamorelin is FDA-approved. AOD-9604 is not FDA-approved (Phase 2 (failed; reclassification pending)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Common side effects of AOD-9604 include Injection site reactions, Headache, Chest tightness (rare). Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideAOD-9604 is a modified peptide fragment of the C-terminus of human growth hormone (amino acids 176-191). It was designed to retain the fat-burning properties of HGH while avoiding effects on blood sug...
View Full AOD-9604 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tesamorelin and AOD-9604 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.